JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy

Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

LabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media

Lonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post

Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN

Thermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance

eLifeThe NTR/prodrug revolution: Tools for controlling cell loss and regeneration

Bio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks

10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com

Eli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits

PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma

Endpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact

AgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.st